Jon Faiz Kayyem - May 31, 2024 Form 4 Insider Report for Inhibrx Biosciences, Inc. (INBX)

Role: Director
Signature: /s/ Kelly Deck, as attorney-in-fact to Jon Faiz Kayyem
Stock symbol: INBX
Transactions as of: May 31, 2024
Transactions value $: $4,927,580
Form type: 4
Date filed: 6/4/2024, 05:27 PM
Previous filing: May 30, 2024
Next filing: Jun 7, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	INBX	Common Stock	Purchase	$1.13M	+70.2K	+8.71%	$16.14^*	876K	May 31, 2024	By The Jon F. Kayyem and Paige Gates-Kayyem Family Trust	F1
transaction	INBX	Common Stock	Purchase	$777K	+46.8K	+5.34%	$16.61^*	923K	Jun 3, 2024	By The Jon F. Kayyem and Paige Gates-Kayyem Family Trust	F2
transaction	INBX	Common Stock	Purchase	$1.45M	+80.7K	+8.75%	$17.90^*	1M	Jun 3, 2024	By The Jon F. Kayyem and Paige Gates-Kayyem Family Trust	F3
transaction	INBX	Common Stock	Purchase	$1.14M	+65.3K	+6.51%	$17.44^*	1.07M	Jun 4, 2024	By The Jon F. Kayyem and Paige Gates-Kayyem Family Trust	F4
transaction	INBX	Common Stock	Purchase	$433K	+23.7K	+2.22%	$18.24^*	1.09M	Jun 4, 2024	By The Jon F. Kayyem and Paige Gates-Kayyem Family Trust	F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The shares were purchased in multiple transactions at prices ranging from $15.75 to $16.25, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
F2	The shares were purchased in multiple transactions at prices ranging from $16.25 to $16.75, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
F3	The shares were purchased in multiple transactions at prices ranging from $17.40 to $18.10, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
F4	The shares were purchased in multiple transactions at prices ranging from $17.01 to $18.00, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
F5	The shares were purchased in multiple transactions at prices ranging from $18.01 to $18.50, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.